» Articles » PMID: 30302045

Role of Peripheral Inflammation in Hepatic Encephalopathy

Overview
Publisher Elsevier
Specialty Gastroenterology
Date 2018 Oct 11
PMID 30302045
Citations 21
Authors
Affiliations
Soon will be listed here.
Abstract

A growing body of evidence now highlights a key role for systemic inflammation in altering behavior and mood in patients with liver disease. How inflammation occurring in the periphery in the context of liver disease, communicates with the brain to mediate changes in neurotransmission and thereby behavior is incompletely understood. Traditional routes of communication between the periphery and the brain involve neural (i.e. vagal afferent nerves) and humoral (blood-borne) pathways, with increased circulating levels of endotoxin and cytokines (especially Tumor Necrosis Factor α, TNFα) that occur during systemic inflammatory responses, as being primarily implicated in mediating signaling via these pathways. However, in recent years communication via peripheral immune-cell-to-brain and the gut-microbiota-to-brain routes have received increasing attention in the context of liver disease for their ability to modulate brain function, and generate a spectrum of symptoms ranging from fatigue and altered mood to overt Hepatic Encephalopathy (HE). In this review, we discuss periphery-to-brain communication pathways and their potential role in mediating systemic inflammation-associated alterations in behavior, that are in turn ultimately part of a spectrum of brain changes linked to the development of clinically apparent HE.

Citing Articles

Drug Utilization of Rifaximin-α in Patients with Hepatic Encephalopathy: Evidence from Real Clinical Practice in Italy.

Perrone V, Usala M, Veronesi C, Cappuccilli M, Degli Esposti L Medicina (Kaunas). 2025; 61(2).

PMID: 40005338 PMC: 11857196. DOI: 10.3390/medicina61020221.


A transient blood IL-17 increase triggers neuroinflammation in cerebellum and motor incoordination in hyperammonemic rats.

Arenas Y, Montoliu C, Llansola M, Felipo V J Neuroinflammation. 2024; 21(1):314.

PMID: 39616376 PMC: 11608494. DOI: 10.1186/s12974-024-03310-5.


Correlation of ammonia and blood laboratory parameters with hepatic encephalopathy: A systematic review and meta-analysis.

Sepehrinezhad A, Moghaddam N, Shayan N, Negah S PLoS One. 2024; 19(9):e0307899.

PMID: 39226259 PMC: 11371226. DOI: 10.1371/journal.pone.0307899.


Anti-inflammatory strategies for hepatic encephalopathy: preclinical studies.

Pinto Coelho Santos R, de Brito Toscano E, Rachid M Arq Neuropsiquiatr. 2023; 81(7):656-669.

PMID: 37487550 PMC: 10371400. DOI: 10.1055/s-0043-1767819.


Gut Dysbiosis and Blood-Brain Barrier Alteration in Hepatic Encephalopathy: From Gut to Brain.

Shahbazi A, Sepehrinezhad A, Vahdani E, Jamali R, Ghasempour M, Massoudian S Biomedicines. 2023; 11(5).

PMID: 37238943 PMC: 10215854. DOI: 10.3390/biomedicines11051272.


References
1.
Dirchwolf M, Podhorzer A, Marino M, Shulman C, Cartier M, Zunino M . Immune dysfunction in cirrhosis: Distinct cytokines phenotypes according to cirrhosis severity. Cytokine. 2015; 77:14-25. DOI: 10.1016/j.cyto.2015.10.006. View

2.
Tillisch K, Labus J, Kilpatrick L, Jiang Z, Stains J, Ebrat B . Consumption of fermented milk product with probiotic modulates brain activity. Gastroenterology. 2013; 144(7):1394-401, 1401.e1-4. PMC: 3839572. DOI: 10.1053/j.gastro.2013.02.043. View

3.
Dhiman R, Rana B, Agrawal S, Garg A, Chopra M, Thumburu K . Probiotic VSL#3 reduces liver disease severity and hospitalization in patients with cirrhosis: a randomized, controlled trial. Gastroenterology. 2014; 147(6):1327-37.e3. DOI: 10.1053/j.gastro.2014.08.031. View

4.
Bajaj J, Heuman D, Sanyal A, Hylemon P, Sterling R, Stravitz R . Modulation of the metabiome by rifaximin in patients with cirrhosis and minimal hepatic encephalopathy. PLoS One. 2013; 8(4):e60042. PMC: 3615021. DOI: 10.1371/journal.pone.0060042. View

5.
Capuron L, Miller A . Immune system to brain signaling: neuropsychopharmacological implications. Pharmacol Ther. 2011; 130(2):226-38. PMC: 3072299. DOI: 10.1016/j.pharmthera.2011.01.014. View